Quantcast

Latest Medical statistics Stories

2014-07-21 12:25:16

ALBANY, New York, July 21, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "E-Clinical Solution Software Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global microfluidic device market was valued at USD 3,005 million in 2014 and is expected to grow at a CAGR of 13.8% from 2014 to 2020, to reach an estimated value of USD 6,515.3 million in 2020. Browse the full E-Clinical...

2014-06-23 04:20:31

LONDON, June 23, 2014 /PRNewswire/ -- Highlights: - Creation of an international CRO with complete service offering from Phase I to Phase IV post-authorisation studies - Appointment of a highly experienced Board, including Professor Trevor Jones CBE, Chairman, Ronald Openshaw, Chief Executive Officer and Professor Sir Christopher Evans, Non-Executive Director - Completed with GBP12.5m of funds raised from Welsh...

2014-06-16 12:29:16

Aspire IRB and Midlands IRB become part of the WCG family, further expanding its geographic and program reach PRINCETON, N.J., June 16, 2014 /PRNewswire/ -- The WIRB-Copernicus Group ("WCG"), the world's largest provider of regulatory and ethical review services for clinical research, announced today that two independent review boards (IRBs) - Aspire IRB and Midlands IRB - have joined the Group. Located near San Diego, CA and Kansas City, MO, respectively, these companies expand...

2014-06-16 08:29:45

PHILADELPHIA, June 16, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") is launching two new global initiatives enabled by broad participation and collaboration across the global research and development (R&D) community: develop a position on the best and most efficient methods for redacting privacy information found in clinical study reports and an approach for the anonymization of patient level data shared with the broader healthcare community; and develop a...

2014-06-04 08:30:14

SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce the distribution of a letter from Hojabr Alimi, the Company's Chairman, Chief Executive Officer and Chief Science Officer, to its stockholders on Form 8-K on June 3, 2014. A download of the full PDF of this...

2014-06-04 04:21:45

VIENNA, June 4, 2014 /PRNewswire/ -- AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients. Upon treatment with AD04, effects consistent with disease modification were achieved for at least 18 months in 47% of treated patients. This beneficial effect was dose dependent and more effective in...

2014-06-02 12:29:04

Results of CISCRP Study Provide New Insights Into How to Engage the Public and Patients PRINCETON, N.J., June 2, 2014 /PRNewswire/ -- inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials, in collaboration with The Center for Information and Study on Clinical Research Participation (CISCRP) has released the results of research showing public perceptions of clinical trials has improved - good news for companies hoping to recruit for a trial. The...

2014-05-27 08:27:36

SYDNEY and BEDMINSTER, N.J., May 27, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Moxduo New Drug Application (NDA) for the treatment of moderate to severe acute pain. The Agency stated that there was not sufficient evidence to support approval of Moxduo at this time. The Agency indicated clinical information demonstrating a clear...

2014-05-22 08:31:11

SAN FRANCISCO, May 22, 2014 /PRNewswire/ -- PULSE enables highly customized IRT trial design while maintaining endpoint's signature 30-Day delivery timeline endpoint Clinical, Inc., a leading provider of Interactive Response Technology (IRT) systems via phone (IVRS), web (IWRS) and mobile (IMRS) for global clinical trials, today announced the launch of its next-generation PULSE 3.0 platform. The enhanced PULSE platform provides highly customized configuration and...

2014-05-19 08:28:29

SAN FRANCISCO, May 19, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel, M.D., will serve as the Company's new Senior Vice President, Drug Development & Chief Medical Officer effective today. Dr. Gergel will have oversight for the company's clinical strategy and activities, including direct supervision of clinical research, clinical operations, medical affairs, regulatory...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related